Sartorius Stedim Biotech (FR:DIM)
:DIM
Want to see FR:DIM full AI Analyst Report?
DIM Stock Chart & Stats
€188.70
€3.85(1.94%)
At close: 4:00 PM EST
€188.70
€3.85(1.94%)
Day’s Range― - ―
52-Week Range€150.00 - €224.00
Previous CloseN/A
Volume6.35K
Average Volume (3M)78.09K
Market Cap
€17.41B
Enterprise Value€19.42B
Total Cash (Recent Filing)€521.20M
Total Debt (Recent Filing)€2.61B
Price to Earnings (P/E)64.9
Beta1.42
Next Earnings
Jul 23, 2026EPS Estimate
1.3Next Dividend Ex-DateN/A
Dividend Yield0.31%
Share Statistics
EPS (TTM)2.75
Shares Outstanding97,330,410
10 Day Avg. Volume78,938
30 Day Avg. Volume78,094
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)5.00
Price to Sales (P/S)6.89
P/FCF Ratio140.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€232.63Price Target Upside23.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)5.1
Revenue Forecast (FY)€3.17B
Bulls Say, Bears Say
Bulls Say
Recurring Consumable RevenueSartorius benefits from durable, repeatable revenue because single-use consumables (bags, tubing, filters) are continuously consumed in bioprocessing. This creates sticky demand, predictable recurring cash flows and customer switching costs tied to validated production workflows, supporting stability over months.
Sharp TTM Revenue Rebound With Solid Operating MarginsA 57% TTM revenue rebound alongside EBIT ~17% and EBITDA ~28% indicates robust end-market demand and operational leverage. Sustained top-line recovery combined with solid operating profitability signals capacity to absorb fixed costs and supports earnings resilience as biopharma production ramps over the next several months.
Improving Leverage And Balance-sheet RepairDebt-to-equity decline from ~1.4 to ~0.64 reflects meaningful balance-sheet repair, lowering financial risk and improving flexibility. Reduced leverage enhances capacity for targeted capex, working-capital management or selective M&A without overburdening cash flows, strengthening the firm's medium-term financial position.
Bears Say
Multi-year Margin CompressionMargins remain materially below recent historical peaks, suggesting structural pressure from product mix shifts, pricing, or cost inflation. Even with revenue recovery, reduced gross and net margins limit the company's ability to translate sales into sustainable profit growth and compress long-term return potential.
Weak Free-cash-flow ConversionFree-cash-flow conversion is low relative to operating earnings, indicating higher reinvestment needs or working-capital drag. This limits available cash for debt reduction, shareholder returns or strategic investments and constrains financial flexibility if demand or margins deteriorate in the coming months.
Modest ROE With Sizeable Remaining DebtROE around 6–7% signals the equity base is delivering modest returns versus prior peaks. Coupled with a material absolute debt load, the company must drive meaningful margin or revenue improvements to lift returns, otherwise shareholder returns and reinvestment capacity may remain constrained.
Sartorius Stedim Biotech News
DIM FAQ
What was Sartorius Stedim Biotech’s price range in the past 12 months?
Sartorius Stedim Biotech lowest stock price was €150.00 and its highest was €224.00 in the past 12 months.
What is Sartorius Stedim Biotech’s market cap?
Sartorius Stedim Biotech’s market cap is €17.41B.
When is Sartorius Stedim Biotech’s upcoming earnings report date?
Sartorius Stedim Biotech’s upcoming earnings report date is Jul 23, 2026 which is in 45 days.
How were Sartorius Stedim Biotech’s earnings last quarter?
Sartorius Stedim Biotech released its earnings results on Apr 23, 2026. The company reported €1.17 earnings per share for the quarter, missing the consensus estimate of €1.211 by -€0.041.
Is Sartorius Stedim Biotech overvalued?
According to Wall Street analysts Sartorius Stedim Biotech’s price is currently Undervalued.
Does Sartorius Stedim Biotech pay dividends?
Sartorius Stedim Biotech pays a Notavailable dividend of €0.69 which represents an annual dividend yield of 0.31%. See more information on Sartorius Stedim Biotech dividends here
What is Sartorius Stedim Biotech’s EPS estimate?
Sartorius Stedim Biotech’s EPS estimate is 1.3.
How many shares outstanding does Sartorius Stedim Biotech have?
Sartorius Stedim Biotech has 97,330,410 shares outstanding.
What happened to Sartorius Stedim Biotech’s price movement after its last earnings report?
Sartorius Stedim Biotech reported an EPS of €1.17 in its last earnings report, missing expectations of €1.211. Following the earnings report the stock price went down -14.185%.
Which hedge fund is a major shareholder of Sartorius Stedim Biotech?
Currently, no hedge funds are holding shares in FR:DIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
DIM Stock 12 Month Forecast
Average Price Target
€232.63
▲(23.28% Upside)
Technical Analysis
Options Prices
Currently, No data available
---